Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 12Recruiting 6Unknown 3Terminated 3Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

pembrolizumab 2Specimen Handling 2Propranolol 2talimogene laherparepvec 1sargramostim 1romiplostim 1propranolol CR 1imisopasem manganese 1gusacitinib 1dabrafenib 1cobimetinib 1cemiplimab 1aldesleukin 1Vemurafenib 1Vaccines 1Surgical Procedures, Operative 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Practice Guidelines as Topic 1Paclitaxel 1Nivolumab 1Nanoparticles 1Microscopy, Confocal 1Magnetic Resonance Spectroscopy 1Ketones 1Interleukin-2 1Glucose 1Drug Therapy 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Surgical Procedures, Operative × Dermatologic × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡